Sign inJoin waitlistJoin the waitlist

Jorge Castillo

Clinical Director, Bing Center for Waldenström Macroglobulinemia · Mass General Brigham

Credentials: · · · ·

History

Bing Center for Waldenström Macroglobulinemia · Mass General Brigham
Present
Mass General Brigham
Present

Hematology and Medical Oncology
Rhode Island Hospital/Brown University Health
1999–2002
Internal Medicine
MetroWest Medical Center-Framingham Union Hospital
1996–1999
Doctor of Medicine
1992–1996

Research

Ibrutinib in previously treated Waldenström's macroglobulinemia
New England Journal of Medicine · 2015 · 796 citations
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study
Blood · 2020 · 402 citations
Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
Blood · 2014 · 391 citations

Steven Treon
160 papers
Shayna Sarosiek
64 papers
Andrew Branagan
34 papers
MM
Manit Munshi
30 papers
Adam Olszewski
28 papers
CF
Catherine Flynn
28 papers
Irene Ghobrial
22 papers
RM
Roberto Miranda
21 papers
Eric Winer
20 papers
Lia Palomba
19 papers
John Reagan
17 papers · 7 as a fellow
Prashant Kapoor
17 papers

Clinical trials

Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
Principal investigator · Active not recruiting · Phase 2
Dana-Farber Cancer Institute
2023–2033
Ibrutinib + Venetoclax in Untreated WM
Principal investigator · Active not recruiting · Phase 2
Dana-Farber Cancer Institute
2020–2028
Dasatinib In Waldenström Macroglobulinemia
Principal investigator · Terminated · Phase 1
Jorge J. Castillo, MD
2019–2021
A Study of Daratumumab in Patients With Relapsed or Refractory Waldenström Macroglobulinemia
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2017–2021